NICE overturns previous decision, recommends Merck and Pfizer’s Bavencio
Following successful appeals, the therapy has been recommended for all eligible bladder cancer patients
11th April 2022
Latest news
NICE recommends Koselugo for the treatment of neurofibromatosis type 1
Alexion Pharma UK, AstraZeneca’s Rare Disease group, announces the recommendation of its pivotal neurofibromatosis treatment
8th April 2022
UK patients granted early access for radioligand therapy in advanced prostate cancer
Patients with the life-threatening disease are set to benefit from the Early Access to Medicines Scheme
8th April 2022
Hundreds of urothelial cancer patients to receive new treatment
NICE recommends avelumab as treatment for adults with locally advanced or metastatic urothelial cancer
7th April 2022
Kynos Therapeutics targets inflammation-driven illness
Spin-off company will focus on developing therapies in areas of inflammation and immunometabolism
7th April 2022
Alpha brain waves can predict post-surgery pain
A technique developed by the University of Birmingham demonstrates link between patients’ alpha brain waves and responses to pain
6th April 2022
Gilead Sciences opens new drug development hub in Dublin
New Dublin development office will be responsible for paediatric clinical trials for seven products across 18 countries
6th April 2022
Novartis presents positive new data on relapsing MS treatment
Data has shown that treatment with Kesimpta is associated with fewer relapses and reduced risk of worsening disability
5th April 2022
Patent granted for Evonetix’s thermally-controlled DNA synthesis
In contrast to conventional methods, Evonetix uses thermal control which offers greater accuracy and selectivity
5th April 2022
AbbVie and We Are Pioneer Group link to accelerate life-changing innovations
Golden Ticket programme is open to early-stage life sciences companies and biotech start-ups which are focusing on cutting edge therapies
4th April 2022
UK government awards Croda International £15.9m grant for manufacturing facility
Investments will enhance the development of lipid systems manufacturing, while also boosting the development of gene therapies
4th April 2022
Parsortix system identifies key drug targets in cancer metastasis
Study demonstrates ability of the Parsortix system to isolate circulating tumour cells, targeting the metastatic spread of cancer
1st April 2022
NICE recommends flash devices to type 1 diabetes patients
New technology could reduce finger pricking by 50% while also providing patients with continuous data about blood sugar levels
1st April 2022
Positive results for Cerevance’s Parkinson’s drug
In phase 2 trials, the drug reduced ‘OFF time’ which refers to periods of the day when Parkinson’s symptoms recur despite medication
31st March 2022
Mission Therapeutics launches clinical trial for kidney disease therapy
MTX652 has advanced through preclinical regulatory toxicology studies and is ready for a phase 1 trial
31st March 2022
